Therapeutic goals and treatment response evaluation in moderate to severe psoriasis: an experts opinion document
暂无分享,去创建一个
Á. González-Cantero | I. Belinchón Romero | J. C. Carrascosa Carrillo | C. Ferrándiz Foraster | E. Daudén
[1] T. Dilla,et al. Patient-physician discrepancy in the perception of immune-mediated inflammatory diseases: rheumatoid arthritis, psoriatic arthritis and psoriasis. A qualitative systematic review of the literature , 2020, PloS one.
[2] G. Pellacani,et al. A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate‐to‐severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO‐BIO‐REAL) , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.
[3] A. Armstrong,et al. Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis. , 2020, JAMA dermatology.
[4] D. Shrom,et al. Understanding Treatment Preferences in Patients with Moderate to Severe Plaque Psoriasis in the USA: Results from a Cross-Sectional Patient Survey , 2019, Dermatology and Therapy.
[5] Jacqueline Pich. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. , 2019, International journal of evidence-based healthcare.
[6] B. Strober,et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with phototherapy. , 2019, Journal of the American Academy of Dermatology.
[7] B. Strober,et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. , 2019, Journal of the American Academy of Dermatology.
[8] M. Tauber,et al. French guidelines on the use of systemic treatments for moderate‐to‐severe psoriasis in adults , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.
[9] L. Naldi,et al. A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey , 2018, The British journal of dermatology.
[10] A. Florek,et al. Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review , 2018, Archives of Dermatological Research.
[11] P. Gisondi,et al. European S3‐Guideline on the systemic treatment of psoriasis vulgaris – Update Apremilast and Secukinumab – EDF in cooperation with EADV and IPC , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.
[12] L. Coates,et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017 , 2017, The British journal of dermatology.
[13] L. Cordingley,et al. ‘New to me’: changing patient understanding of psoriasis and identifying mechanisms of change. The Pso Well® patient materials mixed‐methods feasibility study , 2017, The British journal of dermatology.
[14] L. Naldi,et al. Italian guidelines on the systemic treatments of moderate‐to‐severe plaque psoriasis , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.
[15] I. Belinchón,et al. Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature , 2016, Patient preference and adherence.
[16] L. Puig,et al. Consensus document on the evaluation and treatment of moderate‐to‐severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.
[17] A. Nast,et al. Methods Report: European S3‐Guidelines on the systemic treatment of psoriasis vulgaris – update 2015 – EDF in cooperation with EADV and IPC , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.
[18] P. Gisondi,et al. European S3‐Guidelines on the systemic treatment of psoriasis vulgaris – Update 2015 – Short version – EDF in cooperation with EADV and IPC , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.
[19] L. Cordingley,et al. Patient‐reported outcome measures in psoriasis: the good, the bad and the missing! , 2015, The British journal of dermatology.
[20] R. Ruiz-Villaverde,et al. Directrices del grupo español de psoriasis (GEP) basadas en la evidencia para el uso de medicamentos biológicos en pacientes con psoriasis en localizaciones de difícil tratamiento (uñas, cuero cabelludo, palmas y plantas) , 2014 .
[21] J. M. Carrascosa,et al. Prevalence of psoriasis in Spain in the age of biologics. , 2014, Actas dermo-sifiliograficas.
[22] S. Marron,et al. Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: on efficacy and choice of treatment. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. , 2013, Actas dermo-sifiliograficas.
[23] J. M. Carrascosa,et al. Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis con agentes biológicos, 2013. I . Consideraciones de eficacia y selección del tratamiento , 2013 .
[24] S. Shumack,et al. Treatment goals for moderate to severe psoriasis: An Australian consensus , 2013, The Australasian journal of dermatology.
[25] J. Cappelleri,et al. Effect of Biologic Agents on Non-PASI Outcomes in Moderate-to-Severe Plaque Psoriasis: Systematic Review and Meta-Analyses , 2012, Dermatology and Therapy.
[26] C. Griffiths,et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus , 2010, Archives of Dermatological Research.
[27] A. Nast,et al. Low prescription rate for systemic treatments in the management of severe psoriasis vulgaris and psoriatic arthritis in dermatological practices in Berlin and Brandenburg, Germany: results from a patient registry , 2008, Journal of the European Academy of Dermatology and Venereology : JEADV.
[28] C. F. Foraster,et al. Impacto de la psoriasis en la calidad de vida relacionada con la salud , 2007 .
[29] S. Puig,et al. Prevalence of psoriasis in Spain (Epiderma Project: phase I) , 2001, Journal of the European Academy of Dermatology and Venereology : JEADV.
[30] Robert J G Chalmers,et al. Assessing psoriasis severity and outcomes for clinical trials and routine clinical practice. , 2015, Dermatologic clinics.
[31] A. García‐Díez,et al. [Impact of psoriasis on health-related quality of life]. , 2007, Medicina clinica.
[32] H. Williams,et al. A systematic review of treatments for severe psoriasis. , 2000, Health technology assessment.